Hudson Bay Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-255
Closed -$32.6K – 1725
2026
Q1
$32.6K Buy
+255
New +$31.8K ﹤0.01% 1299
2025
Q2
– Sell
-135,318
Closed -$11M – 1679
2025
Q1
$11M Buy
+135,318
New +$12.1M 0.03% 376
2024
Q2
– Sell
-108,000
Closed -$10.2M – 964
2024
Q1
$10.2M Hold
108,000
– – 0.06% 174
2023
Q4
$9.64M Buy
+108,000
New +$8.02M 0.06% 186
2022
Q4
– Sell
-5,000
Closed -$397K – 1131
2022
Q3
$397K Sell
5,000
-35,000
-88% -$2.95M ﹤0.01% 904
2022
Q2
$2.97M Buy
+40,000
New +$3M 0.02% 657
2020
Q3
– Sell
-94,500
Closed -$10.6M – 640
2020
Q2
$10.6M Buy
+94,500
New +$9.31M 0.19% 92

Other funds holding XBI

Hudson Bay Capital Management's XBI Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 255 shares — an estimated $32.6K sold.

Hudson Bay Capital Management first reported a position in XBI in Q2 2020 and held it in 7 quarters. The position peaked at $11M in Q1 2025. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 255 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $32.6K.
  • Hudson Bay Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 7 quarters.
  • Hudson Bay Capital Management's State Street SPDR S&P Biotech ETF position peaked at $11M in Q1 2025.
  • 936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.